SEP 29, 2026 · JOURNAL ARTICLE
Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France
The Breast
Trastuzumab deruxtecan (T-DXd) is the current standard second-line therapy for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), and it has b